NCT04056975View on ClinicalTrials.gov

Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

PHASE1UnknownINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 15, 2019

Primary Completion Date

September 30, 2021

Study Completion Date

January 27, 2022

Conditions
Relapsed or Refractory B-cell Lymphoma
Interventions
BIOLOGICAL

Recombinant Anti-CD19m-CD3 Antibody Injection

Intravenous Infusion

Sponsors
All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

lead

EVIVE Biotechnology

INDUSTRY